LL-37 but Not 25-Hydroxy-Vitamin D Serum Level Correlates with Healing of Venous Leg Ulcers.
Human cathelicidin, LL-37, is small antimicrobial peptide, which reveals also some immunomodulatory and proangiogenic properties and, therefore, may promote wound healing. The expression of LL-37 is controlled by various factors, including vitamin D. Thus, any disturbances in vitamin D level may influence LL-37 production and, possibly, affect wound healing. Since deficiency of vitamin D was identified as a common problem in the population, this proof of concept study aimed to verify the relationship between serum levels of LL-37, vitamin D, and healing rate of venous leg ulcers. The study involved small group (n = 19) of patients with venous leg ulcers. Apart from non-venous ulcer aethiology, compression intolerance, active vein thrombosis, and wound infection, the exclusion criteria concerned also kidney insufficiency. The results of the analysis of wound healing rates were correlated with patients' serum levels of 25(OH) vitamin D and LL-37. In addition, serum levels of pro-inflammatory cytokines (IL-6, IL-8, and TNF) were analyzed. We have found strong association between serum concentrations of LL-37 and the healing rates in patients with leg ulcers. Despite the fact that 25(OH) vitamin D levels in all patients were below the normal range, they did not show any correlation with healing rates. Furthermore, no association was observed between serum levels of 25(OH) vitamin D and LL-37. No significant correlation between tested pro-inflammatory cytokines and healing rate, LL-37, or 25(OH) vitamin D levels was also observed. Regardless of small study group, our results suggest that the assessment of serum concentration of LL-37, but not 25-hydroxy vitamin D, may help in predicting the wound healing efficacy. Moreover, this assessment may be useful in pre-selection of patients, which could benefit from local treatment with exogenous LL-37.
Laboratory of Cell Molecular Biology, Department of Histology and Embryology, Biostructure Research Centre, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.
Alicja
A
Krejner
Laboratory of Cell Molecular Biology, Department of Histology and Embryology, Biostructure Research Centre, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland.|Postgraduate School of Molecular Medicine, Medical University of Warsaw, Warsaw, Poland.|Department of Otolaryngology, Medical University of Warsaw, Warsaw, Poland.
Małgorzata
M
Litwiniuk
Laboratory of Cell Molecular Biology, Department of Histology and Embryology, Biostructure Research Centre, Medical University of Warsaw, Chalubinskiego 5, 02-004, Warsaw, Poland. tomekgrzela@gmail.com.|Clinic of Phlebology, Warsaw, Poland. tomekgrzela@gmail.com.
Tomasz
T
Grzela
D000328:Adult; D000368:Aged; D023181:Antimicrobial Cationic Peptides / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood; D007871:Leg Ulcer / Q000175:diagnosis*; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D014647:Varicose Ulcer / Q000175:diagnosis*; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood; D014945:Wound Healing; D054804:Cathelicidins
D023181:Antimicrobial Cationic Peptides; D015415:Biomarkers; D016207:Cytokines; D018836:Inflammation Mediators; D014807:Vitamin D; C104450:25-hydroxyvitamin D; D054804:Cathelicidins
Cathelicidin; Healing rate; LL-37; Venous leg ulcer; Vitamin D
Arch Dermatol Res. 2014 Nov;306(9):809-21
25168880
J Clin Invest. 2003 Jun;111(11):1665-72
12782669
Future Microbiol. 2009 Nov;4(9):1151-65
19895218
Br J Dermatol. 2015 Aug;173(2):359-69
26094638
Wound Repair Regen. 2008 Jan-Feb;16(1):19-22
18211575
Mini Rev Med Chem. 2015;15(11):953-63
25985946
PLoS One. 2011;6(10):e25333
22031815
Diabetes Metab Syndr. 2013 Jul-Sep;7(3):148-53
23953180
Comput Methods Programs Biomed. 2008 Oct;92(1):135-43
18653259
PLoS One. 2014 Oct 22;9(10):e111355
25337708
Br J Nutr. 2014 Dec 28;112(12):1938-43
25331710
Eur J Immunol. 2011 Oct;41(10):2817-9
21953640
Endocr Connect. 2015 Sep;4(3):163-71
26034120
EMBO Rep. 2009 Aug;10 (8):881-6
19575012
J Invest Dermatol. 2003 Mar;120(3):379-89
12603850
FASEB J. 2005 Jul;19(9):1067-77
15985530
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
21646368
Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19013-7
22025704
Wound Repair Regen. 2014 Sep-Oct;22(5):613-21
25041740
BMC Res Notes. 2012 Oct 24;5:575
23095332
Rheum Dis Clin North Am. 2012 Feb;38(1):125-39
22525848
Rev Col Bras Cir. 2012 Sep-Oct;39(5):401-7
23174792
Exp Dermatol. 2010 Apr;19(4):332-8
19878298
Cent Eur J Immunol. 2015;40(3):391-4
26648787
Exp Dermatol. 2010 Jul 1;19(7):628-32
20100198
Infect Immun. 2008 Sep;76(9):4176-82
18591225
Wound Repair Regen. 2015 Jan-Feb;23(1):14-21
25571764
Br J Community Nurs. 2003;8(9 Suppl):suppl 4-9
14685963
J Leukoc Biol. 2010 Jan;87(1):79-92
19808939
Peptides. 2011 Oct;32(10):1996-2002
21889964
J Am Geriatr Soc. 2015 Sep;63(9):1861-7
26277680
Inflamm Allergy Drug Targets. 2013 Aug;12(4):239-45
23782205
Am J Clin Nutr. 2010 Sep;92(3):603-11
20610636
Cell Immunol. 2012 Nov;280(1):22-35
23246832
Cent Eur J Immunol. 2015;40(2):225-35
26557038
Recent Pat Antiinfect Drug Discov. 2010 Jan;5(1):10-7
19807676
Plast Reconstr Surg. 2006 Jun;117(7 Suppl):35S-41S
16799373
J Bone Joint Surg Am. 2008 Mar;90(3):580-8
18310708
Biomaterials. 2001 May;22(9):903-12
11311009
Adv Exp Med Biol. 2015 ;888:291-305
26663189
Rev Col Bras Cir. 2012;39(1):60-3
22481708